Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GC3110A in healthy adults aged 65 years and older
NCT02917304Phase 3Completed
- Sponsor
- GC Biopharma
- Start
- Oct 2016
- Primary completion
- Dec 2016
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of GCFLU Quadrivalent in influenza, sponsored by GC Biopharma. Primary endpoints: Percentage of Participants Achieving Pre-defined Seroconversion at Day 21 and Percentage of Participants Achieving Pre-defined Seroprotection at Day 21. Started Oct 2016; status: completed.
02
Drugs
GCFLU Quadrivalent
03
Conditions
influenza
Beyond the preview
Go deeper on NCT02917304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02917304.